A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs FAZ 053 (Primary) ; Spartalizumab (Primary)
Indications Advanced breast cancer; Alveolar soft part sarcoma; Carcinoma; Chordoma; Penile cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Proof of concept
Sponsors Novartis Pharmaceuticals

28 Nov 2024 Planned End Date changed from 14 Nov 2024 to 29 Nov 2024.
28 Nov 2024 Planned primary completion date changed from 14 Nov 2024 to 28 Nov 2024.
02 Feb 2024 Planned End Date changed from 14 Jun 2024 to 14 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com